Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

• Post published:October 1, 2022
• Post category:Press Release

Reunion Neuroscience Inc. Announces Results of Annual General and Special Shareholder Meeting

• Post published:September 30, 2022
• Post category:Press Release

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

• Post published:September 30, 2022
• Post category:Press Release

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

• Post published:September 30, 2022
• Post category:Press Release

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases Operations; A Brief Dispatch from ICPR

• Post published:September 30, 2022
• Post category:Psychedelic Bulletin

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

• Post published:September 29, 2022
• Post category:Press Release

Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer

• Post published:September 28, 2022
• Post category:Press Release

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

• Post published:September 28, 2022
• Post category:Press Release

Mindset Pharma Provides Strategic Intellectual Property License to Cybin

• Post published:September 28, 2022
• Post category:Press Release

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

• Post published:September 28, 2022
• Post category:Press Release